{
    "Patient Information": {
        "Patient ID": "N/A",
        "Patient Name": "Jose Petty",
        "Date of Birth": "1969-10-10",
        "Age": 54,
        "Gender": "Male",
        "Contact Information": "N/A",
        "Address": "N/A"
    },
    "Diagnosis Information": {
        "Diagnosis Center": "Lee-Ramirez",
        "Doctor Name": "Dr. Carla Bird",
        "Accession Number": "9846",
        "Date of Diagnosis": "2023-08-10",
        "Date of Report Issuance": "2023-08-16",
        "CLIA Number": "14D2114007",
        "Laboratory Medical Director ": "Dr. Kevin Thompson",
        "Method of Analysis": "Not explicitly stated, assumed NGS",
        "Pipeline Version (Report Version)": "3.2.0"
    },
    "Cancer Information": {
        "Cancer Type": "Acute lymphocytic leukemia (ALL)",
        "Cancer Stage": "Not explicitly stated",
        "Cancer Grade": "Not explicitly stated",
        "Cancer Location in the Body": "Leukemia",
        "Tumor Specimen Source": "Leukemia",
        "Tumor Percentage in Sample": "37%",
        "Normal Specimen Source": "Blood",
        "Date of Tumor Sample Collection": "2023-08-10",
        "Date Tumor Sample Received": "2023-08-13",
        "Date of Normal Sample Collection": "2023-08-12",
        "Date Normal Sample Received": "2023-08-13"
    },
    "Biomarkers": {
        "General Biomarkers": {
            "Microsatellite Instability (MSI)": "Stable",
            "Tumor Mutational Burden (TMB)": "9 m/Mb",
            "Tumor Mutational Burden Percentile": "5%",
            "Loss of Heterozygosity (LOH)": "N/A",
            "Mismatch Repair (MMR) Status": "N/A",
            "PDL1 Expression": "N/A",
            "EBV (Epstein-Barr Virus) Status": "N/A",
            "Other Immunotherapy Markers": "N/A",
            "Low-Coverage Regions": [
                "SDHB"
            ]
        },
        "Gene Mutations": [
            {
                "Gene Name": "PRKCA",
                "DNA Mutation Description": "c.1387G>C",
                "Protein Variant": "p.D463H",
                "Mutation Type": "Spliceregionvariant",
                "Functional Impact": "GOF",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "24.12%",
                "Transcript ID": "N/A",
                "Somatic or Germline": "Somatic",
                "Potentially Actionable or Biologically Relevant": "Potentially Actionable",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "JAK2",
                "DNA Mutation Description": "c.2792A>G",
                "Protein Variant": "p.M929I",
                "Mutation Type": "Nonsense",
                "Functional Impact": "GOF",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "27.28%",
                "Transcript ID": "N/A",
                "Somatic or Germline": "Somatic",
                "Potentially Actionable or Biologically Relevant": "Potentially Actionable",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "FGFR1",
                "DNA Mutation Description": "c.1966A>G",
                "Protein Variant": "p.K656E",
                "Mutation Type": "Nonsense",
                "Functional Impact": "GOF",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "25.83%",
                "Transcript ID": "N/A",
                "Somatic or Germline": "Somatic",
                "Potentially Actionable or Biologically Relevant": "Biologically Relevant",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "FGFR2",
                "DNA Mutation Description": "N/A",
                "Protein Variant": "N/A",
                "Mutation Type": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "N/A",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "Pertinent Negatives"
            },
            {
                "Gene Name": "IDH1",
                "DNA Mutation Description": "N/A",
                "Protein Variant": "N/A",
                "Mutation Type": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "N/A",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "Pertinent Negatives"
            },
            {
                "Gene Name": "TOP2A",
                "DNA Mutation Description": "N/A",
                "Protein Variant": "N/A",
                "Mutation Type": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "N/A",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "Pertinent Negatives"
            }
        ],
        "Immunochemistry Biomarkers": []
    },
    "Therapeutic Information": {
        "FDA-Approved Therapies for Current Diagnosis": [
            {
                "Therapy Name": "KRAS G12C Inhibitors",
                "Therapy Type": "targeted therapy",
                "Medication": "Sotorasib",
                "Evidence Source": "NCCN, Consensus, Non-Small Cell Lung Cancer, MSK OncoKB, Level 1",
                "Associated Biomarker": {
                    "Biomarker Name": "KRASp.G12C G12C-GOF",
                    "Positively/Negatively Associated": "N/A"
                }
            }
        ],
        "FDA-Approved Therapies for Other Indications": [
            {
                "Therapy Name": "KRAS G12C Inhibitors",
                "Therapy Type": "targeted therapy",
                "Medication": "Sotorasib",
                "Evidence Source": "NCCN, Consensus, Non-Small Cell Lung Cancer, MSK OncoKB, Level 1",
                "Associated Biomarker": {
                    "Biomarker Name": "KRASp.G12C G12C-GOF",
                    "Positively/Negatively Associated": "N/A"
                }
            }
        ]
    },
    "Clinical Trials": [
        {
            "Trial Title": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "Phase 2",
            "Trial Location": "City, state - x mi",
            "Therapy Type": "N/A",
            "Medication": "N/A",
            "Associated Mutations": [
                "KRAS"
            ]
        },
        {
            "Trial Title": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "Phase 1/2",
            "Trial Location": "City, state - x mi",
            "Therapy Type": "N/A",
            "Medication": "N/A",
            "Associated Mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "Trial Title": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "Phase 1/2",
            "Trial Location": "City, state - x mi",
            "Therapy Type": "N/A",
            "Medication": "N/A",
            "Associated Mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "Variants of Unknown Significance (VUS)": [
        {
            "Gene Name": "HSP90B1",
            "DNA Alteration": "c.3113A>G",
            "Protein Variant": "p.I66T",
            "Mutation Type": "Spliceregionvariant",
            "Functional Impact": "LOF",
            "Variant Allele Fraction": "8.77%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "BLM",
            "DNA Alteration": "c.2207_2212delinsTAGATTC",
            "Protein Variant": "p.Y736fs*4",
            "Mutation Type": "Nonsense",
            "Functional Impact": "GOF",
            "Variant Allele Fraction": "15.44%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "PHF6",
            "DNA Alteration": "c.3113A>G",
            "Protein Variant": "p.R225X",
            "Mutation Type": "Nonsense",
            "Functional Impact": "LOF",
            "Variant Allele Fraction": "8.08%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "MYCN",
            "DNA Alteration": "c.131_132delinsTT",
            "Protein Variant": "p.P44L",
            "Mutation Type": "Frameshift",
            "Functional Impact": "GOF",
            "Variant Allele Fraction": "1.52%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "KLF1",
            "DNA Alteration": "c.892G>C",
            "Protein Variant": "p.M39L",
            "Mutation Type": "Missensevariant(exon2)",
            "Functional Impact": "GOF",
            "Variant Allele Fraction": "5.52%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "PTCH1",
            "DNA Alteration": "c.3583A>T",
            "Protein Variant": "p.T1195S",
            "Mutation Type": "Frameshift",
            "Functional Impact": "GOF",
            "Variant Allele Fraction": "3.41%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "NOTCH1",
            "DNA Alteration": "c.7398_7399insAGGGACCG",
            "Protein Variant": "p.G1196D",
            "Mutation Type": "Nonsense",
            "Functional Impact": "GOF",
            "Condition": "realize",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Germline"
        },
        {
            "Gene Name": "KLF1",
            "DNA Alteration": "c.892G>C",
            "Protein Variant": "p.M39L",
            "Mutation Type": "Stopgain",
            "Functional Impact": "LOF",
            "Condition": "deal",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Germline"
        }
    ],
    "Additional Indicators": {
        "Prognostic Markers": {
            "description": "Unfavorable Prognosis",
            "recommendation": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "biomarker": "KRASp.G12C Gain-of-function"
        }
    }
}